TURN UP THE HEAT ON PANCREATIC CANCER

Whole body hyperthermia increases survival, improves response rates to treatment and raises quality of life of pancreatic cancer patients.

ElmediX has developed a safe and reliable technology platform that accurately administers the optimal thermal dose to boost conventional treatments.

An unmet medical need

The need for improved pancreatic cancer treatments remains high. Despite advances in chemo-, radio- and immunotherapy, the 5-year overall survival hasn’t improved much in the past decades and remains below 5%.

The mechanisms behind the tumors’ reduced sensitivity can be countered by heating the cells. This can be achieved by (whole-body) hyperthermia, a promising supportive measure to conventional therapies. Thanks to the generic mechanism of action, other cancers with a high unmet medical need such as glioblastoma or melanoma are additional targets on our roadmap.

A new treatment modality

ElmediX introduces long-term whole-body oncothermia.

By bringing the entire body to a temperature of 41.5°C for multiple hours, a cytotoxic effect is achieved, which is stronger in cancer cells. Exposure to heat also increases their sensitivity to chemo- or radiotherapy through a combination of physiological mechanisms.

For a safe and successful treatment, it is essential to accurately monitor and control the temperature throughout the body. ElmediX’ device can precisely regulate the patient’s body temperature combining state-of-the-art thermal sensing catheter data with a proprietary thermal model of the human body.

Building on successful preclinical results obtained through in vitro and in vivo experiments, demonstrating safety and efficacy, a first-in-human clinical trial will be initiated in Q2-Q3 2020.